OneCell Diagnostics, a startup specializing in AI-powered cancer diagnostics, has successfully secured $16 million in Series A funding. This investment will fuel the company's expansion into the US market with its innovative liquid biopsy test, OncoIndx Ikon. OneCell's ultimate goal is to democratize precision oncology by making advanced cancer testing more accessible and affordable. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
